{"title":"Construction and evaluation of risk prediction model for major adverse cardiovascular events in peritoneal dialysis patients.","authors":"Jing Han, Xiaoli Guo, Xuejiao Liu, Jiping Sun, Fang Li, Yi Gao","doi":"10.3389/fneph.2026.1871318","DOIUrl":"10.3389/fneph.2026.1871318","url":null,"abstract":"<p><strong>Background and objectives: </strong>This study developed and validated a robust, clinically applicable risk prediction model for cardiovascular mortality in high-risk peritoneal dialysis patients. The model enables precise individualized risk stratification, supports evidence-based clinical decisions, and facilitates targeted preventive interventions to improve long-term outcomes.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on peritoneal dialysis patients at the Department of Nephrology, First Affiliated Hospital of Xi'an Jiaotong University, from June 2018 to May 2025. Cardiovascular disease served as the primary endpoint. Baseline characteristics and laboratory parameters were compared between groups. Univariate and multivariate regression analyses identified predictors of major adverse cardiovascular events. The predictive model was developed and validated using a 7:3 split after bootstrap resampling.</p><p><strong>Results: </strong>Multivariate analysis identified age, fasting blood glucose, absolute handgrip strength, and left ventricular ejection fraction as significant predictors. ROC curves (AUC > 0.6) and Kaplan-Meier curves (P < 0.05) confirmed their diagnostic and discriminatory value for major adverse cardiovascular events. A nomogram incorporating these four variables was developed. Its AUCs for predicting 3-, 5-, and 8-year cardiovascular event incidence were 0.828 (95% CI: 0.744-0.912), 0.785 (95% CI: 0.702-0.868), and 0.836 (95% CI: 0.744-0.929), respectively-indicating strong predictive discrimination. Using the optimal cut-off, patients were stratified into low- and high-risk groups. Kaplan-Meier analysis showed significant differences in cumulative event incidence at all three time points (P < 0.001), confirming good discrimination. Calibration demonstrated close agreement between predicted and observed outcomes; decision curve analysis supported robust clinical utility.</p><p><strong>Conclusion: </strong>Age, fasting blood glucose, absolute handgrip strength, and left ventricular ejection fraction are independent predictors of MACE in patients receiving PD. We have developed and internally validated a novel, interpretable nomogram-based risk prediction model that demonstrates high discriminative accuracy, calibration fidelity, and clinical utility. This tool holds substantial promise for early identification of high-risk individuals at PD initiation, thereby facilitating timely, personalized cardiovascular risk mitigation strategies.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1871318"},"PeriodicalIF":2.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-09-03eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1908272
Izere Salomon, Yves Ndamukunda, Mukanoheli Solange, Eden Enyew Zeleke
{"title":"Serum uric acid in pediatric metabolic assessment: the scientific rationale for routine screening and the urgent need for age- and sex-specific diagnostic thresholds.","authors":"Izere Salomon, Yves Ndamukunda, Mukanoheli Solange, Eden Enyew Zeleke","doi":"10.3389/fneph.2026.1908272","DOIUrl":"10.3389/fneph.2026.1908272","url":null,"abstract":"","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1908272"},"PeriodicalIF":2.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-08-26eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1767603
Kathrin I Fischer, Krister Cromm, Peter J Blankestijn, Bernard Canaud, Jörgen Hegbrant, Claudia Barth, Mark Woodward, Giovanni F M Strippoli, Andrew Davenport, Michiel L Bots, Matthias Rose
{"title":"Assessment of patient perspectives in the CONVINCE trial in end-stage kidney disease - a domain-guided approach.","authors":"Kathrin I Fischer, Krister Cromm, Peter J Blankestijn, Bernard Canaud, Jörgen Hegbrant, Claudia Barth, Mark Woodward, Giovanni F M Strippoli, Andrew Davenport, Michiel L Bots, Matthias Rose","doi":"10.3389/fneph.2026.1767603","DOIUrl":"10.3389/fneph.2026.1767603","url":null,"abstract":"<p><strong>Background: </strong>Patient-reported outcome (PRO) measures are increasingly used in clinical trials and clinical care to assess symptoms, functioning, and health-related quality of life (HRQoL). In dialysis research, instrument-driven approaches that rely on legacy measures may not fully capture outcomes that matter most to patients or treatment-related experiences such as dialysis-specific fatigue and recovery. Therefore, a patient-informed, domain-guided PRO toolbox for adults with end-stage kidney disease (ESKD) receiving maintenance dialysis was developed and applied in the CONVINCE trial.</p><p><strong>Methods: </strong>A multi-method, triangulation approach was used, comprising: 1) a targeted literature review of PROMs and symptom concepts used in maintenance dialysis research, 2) review of international core outcome initiatives relevant to kidney disease and haemodialysis, 3) semi-structured interviews and focus groups with patients (<i>n</i> = 13) and health care professionals (<i>n</i> = 4). Concepts identified across sources were compiled, compared, and prioritized based on recurrence across evidence sources, salience to patients, anticipated sensitivity to dialysis modality, and feasibility of repeated assessment within the CONVINCE trial.</p><p><strong>Results: </strong>The literature review identified 97 PROMs. Domains and symptom content were extracted from these instruments and mapped against concepts covered by international core outcome initiatives and qualitative data. Triangulation resulted in an ESKD PRO toolbox comprising nine prioritized health domains: general health/health perception, fatigue, physical function, social roles, depression, anxiety, pain, sleep, and cognitive function. Most of these domains could be assessed within the PROMIS<sup>®</sup> health domain framework. To complement these generic domain measures, a dialysis-specific symptom list and additional items to assess dialysis-related fatigue, treatment-related recovery time were included.</p><p><strong>Conclusion: </strong>The ESKD PRO toolbox provides a patient-informed, domain-guided framework for repeated longitudinal assessment of outcomes relevant to patients receiving maintenance dialysis. Its application in CONVINCE illustrates how PROMIS<sup>®</sup> -based domain assessment can be combined with dialysis-specific symptom and fatigue measures to capture treatment-related patient experiences.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1767603"},"PeriodicalIF":2.9,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13553382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148922026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association of neutrophil-to-lymphocyte-platelet ratio with residual renal function in early-stage peritoneal dialysis patients.","authors":"Fei Tian, Tingting Li, Jiayu Duan, Jia Li, Guangpu Li, Dongwei Liu","doi":"10.3389/fneph.2026.1896689","DOIUrl":"10.3389/fneph.2026.1896689","url":null,"abstract":"<p><strong>Background: </strong>To investigate the association between the neutrophil-to-lymphocyte-platelet ratio (NLPR) and residual renal function (RRF) in early-stage peritoneal dialysis (PD) patients, and to evaluate its association with for RRF decline.</p><p><strong>Methods: </strong>This retrospective study included PD patients treated between January 2025 and February 2026. Patients were divided into an early group (dialysis duration 3-12 months) and a late group (>12 months). One extreme NLPR outlier was excluded from the early group, resulting in 23 patients in the early group and 49 in the late group. Spearman's correlation, linear regression, and ROC curve analysis were used.</p><p><strong>Results: </strong>In the early group, NLPR was significantly negatively correlated with residual renal Ccr (<i>r</i> = -0.559), residual renal Kt/V (<i>r</i> = -0.465), eGFR (<i>r</i> = -0.471), nPCR (<i>r</i> = -0.515), and target Kt/V achievement (<i>r</i> = -0.448) (all <i>p</i> < 0.05). Univariate linear regression showed that NLPR significantly predicted residual renal Ccr (B = -1.502, <i>p</i> = 0.006), and it remained independently predictive after adjusting for nPCR (B = -1.592, <i>p</i> = 0.011). ROC curve analysis demonstrated good discriminatory ability for predicting lower RRF, with an AUC of 0.818 (95% CI 0.640-0.996, <i>p</i> = 0.010). The optimal cut-off was 10.372, with 81.8% sensitivity and 58.3% specificity. Subgroup analysis showed a stronger association in males (r = -0.796, <i>p</i> = 0.006).</p><p><strong>Conclusions: </strong>NLPR is significantly associated with RRF in early-stage PD patients. Although it demonstrated good discriminatory ability for RRF status in this cross-sectional study, its predictive value for RRF decline warrants further validation in longitudinal cohort studies.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1896689"},"PeriodicalIF":2.9,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13553526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148922029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-08-24eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1861024
Husain Alturkistani
{"title":"Ultrasound-guided kidney biopsy: a review of what operators need to know.","authors":"Husain Alturkistani","doi":"10.3389/fneph.2026.1861024","DOIUrl":"10.3389/fneph.2026.1861024","url":null,"abstract":"<p><p>Ultrasound-guided kidney biopsy is a key procedure for diagnosing renal parenchymal disease and assessing renal involvement in systemic disorders. This review summarizes indications and contraindications, patient preparation, procedural technique, and post-biopsy monitoring, with emphasis on complication prevention and risk mitigation. Pre-biopsy ultrasound is essential to assess renal size, morphology, and anatomic variants and to plan a safe needle trajectory. Biopsy is typically performed from the lower pole renal cortex in the prone position using a spring-loaded core needle after local anesthesia. Bleeding is the principal complication, so structured observation after the procedure is mandatory.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1861024"},"PeriodicalIF":2.9,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-08-19eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1761672
Bing Lu, Jacqueline P Honerlaw, Yuk-Lam Ho, Daniel Posner, David R Gagnon, Xuan-Mai T Nguyen, Jason L Vassy, J Michael Gaziano, Kelly Cho, Luc Djousse, Peter W F Wilson
{"title":"Acute kidney injury, baseline renal function, troponin, and survival after myocardial infarction.","authors":"Bing Lu, Jacqueline P Honerlaw, Yuk-Lam Ho, Daniel Posner, David R Gagnon, Xuan-Mai T Nguyen, Jason L Vassy, J Michael Gaziano, Kelly Cho, Luc Djousse, Peter W F Wilson","doi":"10.3389/fneph.2026.1761672","DOIUrl":"10.3389/fneph.2026.1761672","url":null,"abstract":"<p><strong>Background: </strong>The roles of chronic kidney disease and acute kidney injury (AKI) as determinants of short- and long-term survival following myocardial infarction (MI) have not been well investigated.</p><p><strong>Methods: </strong>A retrospective analysis of electronic health record data was conducted for U.S. veterans between 2002 and 2015, with up to 15 years of follow-up after MI. Eligible participants included 49,150 veterans with a serum creatinine measurement prior to MI hospitalization. AKI stage was determined by the change between the pre-hospitalization creatinine level and the peak in-hospital measurement. The associations of AKI, estimated glomerular filtration rate (eGFR), and troponin I ratios with survival were evaluated using Cox proportional hazards models.</p><p><strong>Results: </strong>Compared to the no-AKI group, the hazard ratios (HRs) and 95% confidence intervals (CIs) for 30-day mortality were 3.12 (2.87-3.39), 5.12 (4.65-5.65), and 7.81 (6.93-8.81) across worsening stages of AKI. For 15-year mortality, the HRs were 1.76 (1.68-1.85), 2.33 (2.17-2.50), and 2.66 (2.37-2.99). Compared to those with eGFR >60 mL/min/1.73 m², HRs (95% CI) for 30-day mortality were 1.23 (1.13-1.33), 1.46 (1.33-1.59), and 1.92 (1.72-2.13) across decreasing eGFR levels. For 15-year mortality, HRs were 1.21 (1.17-1.25), 1.55 (1.49-1.61), and 2.13 (2.03-2.24). Mortality rates increased with rising troponin I (cTnI) ratios, particularly for 30-day mortality.</p><p><strong>Conclusions: </strong>AKI, baseline eGFR, and troponin levels were associated with both short- and long-term survival following MI. AKI during MI hospitalization was a particularly strong determinant of short-term mortality.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1761672"},"PeriodicalIF":2.9,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148882663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-08-14eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1886887
Lina Maria Serna-Higuita, Sarah Kalmbach, Anja Schork, Nils Heyne, Sandra Beer-Hammer, Silvio Nadalin, Peter Martus, Alfred Königsrainer, Moritz Schmelzle, Markus Quante
{"title":"Age-specific impact of different immunosuppressive regimens on kidney transplant outcomes: clinical evidence from the scientific registry of transplant recipients.","authors":"Lina Maria Serna-Higuita, Sarah Kalmbach, Anja Schork, Nils Heyne, Sandra Beer-Hammer, Silvio Nadalin, Peter Martus, Alfred Königsrainer, Moritz Schmelzle, Markus Quante","doi":"10.3389/fneph.2026.1886887","DOIUrl":"10.3389/fneph.2026.1886887","url":null,"abstract":"<p><strong>Background: </strong>Although older kidney transplant recipients have a higher risk of side effects leading to infection and malignancies, the impact of different immunosuppressive regimens on clinical outcomes in this group remains unclear.</p><p><strong>Methods: </strong>Retrospective cohort study analyzing data from the Scientific Registry of Transplant Recipients database. Kidney transplant recipients were categorized according to age categories (18-64 and >65 years) and immunosuppressive maintenance regimens: tacrolimus/mycophenolate mofetil (Tac-MMF), Tac/mTOR-inhibitor (Tac-mTORi), cyclosporin/MMF (CsA-MMF) and mTORi-MMF. The primary endpoint was overall survival.</p><p><strong>Results: </strong>Among the 112, 952 patients analyzed, overall survival rates at 2-, 3- and 5-years post-transplant were 95.6%, 93.7% and 87.6% respectively. No significant differences in the risk of mortality, graft loss or acute rejection were observed between patients treated with Tac-mTORi and those receiving Tac-MMF. Furthermore, no significant interactions were found between the maintenance immunosuppressive regimens and recipient age groups. Regarding kidney function, younger patients on the Tac-mTORi compared with Tac-MMF regimen exhibited a lower mean eGFR throughout the follow-up period compared to those on Tac-MMF. In contrast to this younger cohort, older patients treated with Tac-mTORi did not experience a significant additional decline in renal function.</p><p><strong>Conclusion: </strong>In this study, Tac-mTORi and Tac-MMF showed comparable results regarding patient survival, graft survival and rejection rates. Because older patients remain at higher risk for drug-related side effects, including infections, metabolic disorders and malignancies, these results highlight the critical need for individually immunosuppressive regimens in older transplant recipients and warrant further prospective validation.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1886887"},"PeriodicalIF":2.9,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13521798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148852030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of hematuria on long term kidney outcomes in adults with immunoglobulin A nephropathy: a systematic literature review and meta-analysis.","authors":"Joel Iff, Ankit Shah, Rajeshwari Nair, Mirko Fillbrunn, Ogo Egbuna, Manish Maski, Rui Huang, Dumingu Aparna Gomes, Edward Tuttle, Whitney Longstaff, Janice Stricker-Shaver, Beth Barber","doi":"10.3389/fneph.2026.1899597","DOIUrl":"10.3389/fneph.2026.1899597","url":null,"abstract":"<p><strong>Introduction: </strong>Hematuria is the most common clinical manifestation of Immunoglobulin A nephropathy (IgAN) and has been associated with adverse long-term kidney outcomes, although its prognostic significance has not been clearly established. This systematic literature review and meta-analysis aimed to evaluate whether hematuria is a prognostic marker of long-term kidney outcomes.</p><p><strong>Methods: </strong>A search of PubMed/MEDLINE and Embase (January 2005 to June 2025) identified studies assessing persistent or single-timepoint measurement of microhematuria or macrohematuria in relation to kidney outcomes. Studies meeting predefined criteria were qualitatively synthesized, and those with comparable outcome definitions were included in meta-analyses using random-effects models.</p><p><strong>Results: </strong>Forty-three studies were included in the systematic literature review, of which 15 study entries from 13 publications were included in meta-analyses. Across studies, persistent microhematuria was consistently associated with worse long-term kidney outcomes. In pooled analyses, microhematuria (both persistent and single-timepoint measurements) was associated with an increased risk of end-stage kidney disease or related outcomes (hazard ratio [HR] 2.33, 95% confidence interval [CI] 1.94-2.80), with a stronger and consistent association observed for persistent microhematuria (HR 2.57, 95% CI 1.94-3.41). Single-timepoint measurement of microhematuria showed a nonsignificant directional association with substantial variability across studies, whereas macrohematuria (predominantly measured at a single timepoint) was associated with improved kidney outcomes (HR 0.56, 95% CI 0.37-0.83).</p><p><strong>Discussion: </strong>These findings support persistent microhematuria as a strong and consistent predictor of kidney failure in IgAN, substantiating its role as a clinically relevant prognostic marker.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1899597"},"PeriodicalIF":2.9,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13506698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148835240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-08-11eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1826486
Chi Wang, Wan He, QingYuan Zheng, Yuan Zhong, Meng Tang, ChunYing Zhang, Yong He
{"title":"Development and validation of a routine urinalysis-based risk stratification model for IgA nephropathy in a multicenter real-world hospital population.","authors":"Chi Wang, Wan He, QingYuan Zheng, Yuan Zhong, Meng Tang, ChunYing Zhang, Yong He","doi":"10.3389/fneph.2026.1826486","DOIUrl":"10.3389/fneph.2026.1826486","url":null,"abstract":"<p><strong>Background: </strong>IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. Routine urinalysis is universally accessible but underutilized for IgAN risk stratification. This study aimed to develop and validate a urinalysis-based risk stratification model for IgAN in a multicenter real-world hospital population.</p><p><strong>Methods: </strong>This retrospective multicenter study was based on routine urinalysis records from 8 hospitals. A total of 354 patients had biopsy-confirmed primary IgAN, and 18,002 controls had no documented IgAN diagnosis after electronic medical record (EMR) review. The dataset was randomly divided into a training cohort (70%) and a hold-out validation cohort (30%). LASSO penalized logistic regression was used for variable selection. Model performance was evaluated by discrimination, calibration, and decision curve analysis (DCA). Bootstrap validation with 1000 resamplings was performed. An 8-variable simplified model was additionally developed.</p><p><strong>Results: </strong>LASSO regression selected 13 variables for the primary full model. The primary model achieved an AUC of 0.849 (95% CI: 0.824-0.873) in the training cohort and 0.861 (95% CI: 0.833-0.890) in the validation cohort. Calibration was good in the training cohort (Brier score = 0.017), while moderate calibration deviation was observed in the validation cohort (Brier score = 0.020). The model yielded a high negative predictive value (>0.99). The 8-variable simplified model retained favorable discrimination with a validation AUC of 0.840.</p><p><strong>Conclusions: </strong>This routine urinalysis-based model may serve as an accessible laboratory-based risk stratification tool for identifying patients with relatively low or elevated predicted probability of IgAN in real-world hospital settings. It should be interpreted as an adjunct to clinical evaluation rather than as a stand-alone diagnostic test or replacement for renal biopsy.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1826486"},"PeriodicalIF":2.9,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13503150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148820582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-08-04eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1861999
Matthew Gross, Aditi Singh, Raj Roshan, Antoine Azar, Duvuru Geetha
{"title":"Immunoglobulin replacement therapy in antineutrophil cytoplasmic antibody-associated vasculitis with rituximab-associated hypogammaglobulinemia: infection outcomes and disease course in a retrospective cohort.","authors":"Matthew Gross, Aditi Singh, Raj Roshan, Antoine Azar, Duvuru Geetha","doi":"10.3389/fneph.2026.1861999","DOIUrl":"https://doi.org/10.3389/fneph.2026.1861999","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate whether immunoglobulin replacement therapy (IgR), initiated for infection prophylaxis in patients with ANCA-associated vasculitis (AAV) receiving rituximab, is associated with changes in infection burden, disease activity, and the ability to de-escalate immunosuppression.</p><p><strong>Methods: </strong>We performed a retrospective single-center study of 16 patients with AAV treated with rituximab who developed secondary hypogammaglobulinemia (IgG <600 mg/dL) and subsequently received IgR between 2014 and 2024. Patients receiving IgR for primary immunodeficiency were excluded. Data collected included demographics, ANCA serotype, relapse history, infection burden, immunosuppressive regimen, and serum IgG levels before and after IgR. Primary outcomes were infections and disease relapse before versus after IgR initiation. Secondary outcomes included changes in serum IgG and rituximab use.</p><p><strong>Results: </strong>Prior to IgR, mean IgG was 287 ± 98 mg/dL, 14/14 patients tested had impaired vaccine responses, and 13/16 (81%) experienced recurrent or severe infections. Seven patients (44%) had at least one disease relapse while on rituximab maintenance. After IgR, mean IgG increased to 1018 ± 234 mg/dL, with normalization in 14/15 (93%). Recurrent or severe infections decreased to 1/16 (6%). Following IgR initiation, no disease relapses were observed during a median follow-up of 29.0 months (IQR 14.5-61.4; range 2.8-127.8), despite rituximab discontinuation in 10 patients and dose-interval extension in the remaining 6 patients. IgR was discontinued in 3 patients without relapse.</p><p><strong>Conclusion: </strong>In this cohort of AAV patients with rituximab-associated hypogammaglobulinemia, IgR demonstrated improved immunoglobulin levels and reduced infection burden and was associated with sustained disease remission despite immunosuppression de-escalation. Further studies are needed to determine whether IgR influences disease activity in AAV.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1861999"},"PeriodicalIF":2.9,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13481165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148802380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}